S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 191.58 CNY 0.32%
Market Cap: 76.8B CNY
Have any thoughts about
Sichuan Biokin Pharmaceutical Co Ltd?
Write Note

Sichuan Biokin Pharmaceutical Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sichuan Biokin Pharmaceutical Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
-ÂĄ769m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ3.8B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ5.9B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Pre-Tax Income
ÂĄ225.5m
CAGR 3-Years
-14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
76.8B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
48.32 CNY
Overvaluation 75%
Intrinsic Value
Price
S

See Also

What is Sichuan Biokin Pharmaceutical Co Ltd's Pre-Tax Income?
Pre-Tax Income
-769m CNY

Based on the financial report for Dec 31, 2023, Sichuan Biokin Pharmaceutical Co Ltd's Pre-Tax Income amounts to -769m CNY.

What is Sichuan Biokin Pharmaceutical Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 1Y
-166%

Over the last year, the Pre-Tax Income growth was -166%.

Back to Top